This educational HoloVision enduring activity will offer the ophthalmology clinician an opportunity to learn more about diversity, equity, and inclusion.  The program aims to increase the participant’s ability to recognize ethnic, racial, and gender variations in the incidence and progression of ocular diseases, along with assessing the social determinants of health responsible for inequities.  Learn more about how to evaluate and minimize unconscious biases in hiring and professional development in ophthalmology and an opportunity to learn more about the importance of diversity in clinical research and learn about tactics that will encourage underrepresented minority enrollment in clinical trials.

RELEASED DATE: April 25, 2024
EXPIRATION DATE: April 25, 2025

This online program is designed to help primary care clinicians who manage patients who have or are at risk for diabetic eye disease. Learn about the importance of early detection and recommended screening guidelines, how to identify patients at higher risk for diabetic eye disease, and multidisciplinary management options to help patients with diabetes preserve vision.

RELEASED DATE: June 12, 2023
EXPIRATION DATE: June 12, 2024

This enduring activity focuses on the use of next-generation therapies such as gene therapy, biosimilars, advanced delivery systems, artificial intelligence, and advancements in pharmacological treatments, including new molecular targets and therapeutic formulations for the management of patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Listen to a retina expert explain the rationale behind these new therapies, as well as the clinical trial data regarding their safety, efficacy, and mechanisms of action to expand treatment options and potentially improve visual outcomes in patients with retinal vascular conditions.

RELEASED DATE: June 08, 2023
EXPIRATION DATE: June 08, 2024

This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological advancements that can help with timely diagnosis and/or effective interval monitoring of nAMD, discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies, and compare the safety, efficacy, and durability of established and emerging therapies for patients with nAMD.

RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024

This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story, along with commentary from a retinal disease expert.

RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024

This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME). Providers will learn about the safety, efficacy, and durability of established and emerging DME therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story along with commentary from a retinal disease expert.

RELEASED DATE: September 08, 2023
EXPIRATION DATE: September 08, 2024

This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME) based on patient-, disease-, and treatment-related factors. Providers will learn about technological advancements that can help with timely diagnosis and/or effective interval monitoring of DME. Listen to a retina expert discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies and compare the safety, efficacy, and durability of established and emerging therapies for patients with DME.

RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024

This interactive, case-based enduring meeting is designed to foster learner collaboration and decision-making for various presentations of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Learn and apply the latest updates in treatment, including novel therapeutic formulations as well as considerations on patient related factors and dosing strategies to individualize care in nAMD and DME.

RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024

This enduring program targets critical issues in nonproliferative diabetic retinopathy (NPDR), including risk for retinopathy development and progression, how early treatment can help prevent progression to vision-threatening complications, and treatment strategies for NPDR. Learn essential elements of assessment and management, as well as clinical trial data on the latest approaches in care, helping to preserve vision in diabetes.

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.